Group 1: Company Performance - Northern Rare Earth expects a net profit of 900 million to 960 million yuan for the first half of 2025, representing a year-on-year increase of 1882.54% to 2014.71% [1] - Muyuan Foods anticipates a net profit of 10.5 billion to 11 billion yuan for the first half of 2025, reflecting a year-on-year growth of 924.6% to 973.39% [2] - Hongta Securities projects a net profit of 651 million to 696 million yuan for the first half of 2025, indicating a year-on-year increase of 45% to 55% [3] Group 2: Business Developments - Dazhihui clarifies that it has not engaged in businesses related to "stablecoins," "virtual asset trading," or "cross-border payments," following a significant stock price fluctuation [4] - Bluetech announces a share transfer agreement where its actual controller will change, with the Ma'anshan Municipal Government becoming the actual controller after the transfer of 18% of shares [5] Group 3: Industry Trends - Jiangsu Electric Power reports a 5.01% year-on-year increase in electricity generation for the first half of 2025 [6] - Jin'an Guoji anticipates a non-recurring net profit growth of 4700% to 6300% for the first half of 2025 [6] - New Beiyang expects a non-recurring net profit growth of 650% to 720% for the first half of 2025 [6]

Group 1 - Huaguang Huaneng's stock has experienced five consecutive trading limits, with a cumulative turnover rate of 29.41% over the past five trading days, indicating potential irrational speculation risk [3] - The company confirms that its production and operational activities are normal, with no significant changes in its fundamentals or business structure [3] Group 2 - Andeli's actual controller Wang An transferred 90% of the shares of BVI Pingan to his daughter Wang Meng, but this transfer does not affect the company's shareholding structure or governance [4] - The controlling shareholder and actual controllers remain unchanged, ensuring the company's governance structure and ongoing operations are unaffected [4] Group 3 - Suntech's indirect controlling shareholder, Suntech Holdings, has had 4.26 million unrestricted circulating shares (8.51% of its holdings, 0.19% of total shares) judicially disposed of, but this is not expected to impact the company's daily operations [5] Group 4 - Three Gorges Energy reported a total power generation of 39.314 billion kWh in the first half of 2025, representing an 8.85% year-on-year increase [6] - The company generated 19.531 billion kWh in the second quarter of 2025, a 6.24% increase compared to the same period last year [6] Group 5 - New Zhonggang's stock has experienced four consecutive trading limits, with no significant media reports or market rumors affecting its stock price [7] - The company confirms that its production and operational status is normal, with no major adjustments in market environment or industry policies [7] Group 6 - ST Yazhen's controlling shareholder Wu Tao's tender offer for 55.1779 million shares (21.00% of total shares) at a price of 5.68 yuan per share has reached its deadline, leading to a one-day suspension of trading [8] Group 7 - Zhongli's wholly-owned subsidiary plans to invest 478 million yuan in a smart logistics equipment project in Jiangsu, with the project covering approximately 120 acres [9][10] Group 8 - Xianda expects a net profit of 130 million to 150 million yuan for the first half of 2025, a year-on-year increase of 2443.43% to 2834.73%, driven by rising product prices and improved operational efficiency [12] - The company's main product, Oxyfluorfen, has seen a price increase, contributing to higher gross margins [12] Group 9 - Morninglight Bio expects a net profit of 202 million to 232 million yuan for the first half of 2025, a year-on-year increase of 102.33% to 132.38%, primarily due to the recovery of cottonseed business [13] Group 10 - Xinlian Electronics anticipates a net profit of 166 million to 198 million yuan for the first half of 2025, reversing a loss from the previous year, largely due to increased non-recurring gains [14] Group 11 - Wohua Pharmaceutical expects a net profit of 37 million to 53 million yuan for the first half of 2025, a year-on-year increase of 233.89% to 378.27%, attributed to improved market adaptation and cost control [15] Group 12 - Yonghe expects a net profit of 255 million to 280 million yuan for the first half of 2025, a year-on-year increase of 126.30% to 148.49%, driven by rising refrigerant prices [16] Group 13 - Shanghai Pharmaceuticals anticipates a net profit of 4.45 billion yuan for the first half of 2025, a year-on-year increase of approximately 52%, mainly due to the acquisition of a 10% stake in Shanghai Hutchison Pharmaceuticals [17] Group 14 - Jingneng Real Estate expects a net loss of 190 million to 210 million yuan for the first half of 2025, primarily due to reduced project turnover and increased expenses [18] Group 15 - Fengfan has won a bid for a project with a value of approximately 337 million yuan from Southern Power Grid, accounting for 10.45% of the company's audited revenue for 2024 [19] Group 16 - Longjian has been awarded a joint bid for a project worth 362 million yuan, with the company responsible for 99.39% of the work [20]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因依賴該等內容而引致之任何損失承擔任何責任。 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.* ( 於中華人民共和國註冊成立的股份有限公司 ) (股份代碼: 02607) 2025年半年度業績預增公告 本公告乃上海醫藥集團股份有限公司（「本公司」，連同其附屬公司合稱為「本集團」）根 據香港聯合交易所有限公司證券上市規則（「上市規則」）第 13.09(2)及 13.10B 條及證券及 期貨條例（香港法例第 571章）第 XIVA部的內幕消息條文（定義見上市規則）作出。 一、本期業績預告情況 （一）業績預告期間 2025 年 1 月 1 日至 2025 年 6 月 30 日。 （二）業績預告情況 經本公司財務部門初步測算，本公司預計 2025 年上半年度實現歸屬於母公司所有者的 淨利潤為人民幣 44.50 億元，與上年同期相比，將增加人民幣 15.08 億元，同比增長約 52%。 本公司於 ...

[Key Highlights](index=1&type=section&id=Key%20Highlights) The company anticipates a significant increase in net profit attributable to shareholders for the first half of 2025 2025 First Half Performance Forecast Overview | Metric | Amount (RMB) | Change | Year-on-Year Growth | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders (Estimated) | 4.45 billion | Increased by 1.508 billion | Approx. 52% | [Current Period Performance Forecast](index=1&type=section&id=I.%20Current%20Period%20Performance%20Forecast) This section details the company's financial performance forecast for the first half of 2025, including the reporting period and key profit estimates [Performance Forecast Period](index=1&type=section&id=(I)%20Performance%20Forecast%20Period) The performance forecast covers the financial period from January 1, 2025, to June 30, 2025 - The performance forecast period is from January 1, 2025, to June 30, 2025[3](index=3&type=chunk) [Performance Forecast Details](index=1&type=section&id=(II)%20Performance%20Forecast%20Details) The company expects net profit attributable to shareholders for the first half of 2025 to reach 4.45 billion RMB, representing an approximate 52% year-on-year increase 2025 First Half Net Profit Attributable to Shareholders Forecast | Metric | Amount (RMB) | Change | Year-on-Year Growth | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders (Estimated) | 4.45 billion | Increased by 1.508 billion | Approx. 52% | [Unaudited Statement](index=1&type=section&id=(III)%20Unaudited%20Statement) The financial data disclosed in this performance forecast is a preliminary estimate by the company's finance department and has not been audited by a certified public accountant - The data in this performance forecast has not been audited by a certified public accountant[3](index=3&type=chunk) [Prior Period Operating Performance and Financial Status](index=1&type=section&id=II.%20Prior%20Period%20Operating%20Performance%20and%20Financial%20Status) This section provides an overview of the company's operating performance and financial status for the same period in the previous year [Prior Period Net Profit Attributable to Shareholders](index=1&type=section&id=(I)%20Prior%20Period%20Net%20Profit%20Attributable%20to%20Shareholders) Net profit attributable to shareholders for the prior period (first half of 2024) was 2.942 billion RMB Prior Period Net Profit Attributable to Shareholders | Metric | Amount (RMB) | | :--- | :--- | | Net Profit Attributable to Shareholders | 2.942 billion | [Prior Period Earnings Per Share](index=1&type=section&id=(II)%20Prior%20Period%20Earnings%20Per%20Share) Earnings per share for the prior period (first half of 2024) was 0.79 RMB Prior Period Earnings Per Share | Metric | Amount (RMB) | | :--- | :--- | | Earnings Per Share | 0.79 | [Main Reasons for Performance Increase](index=1&type=section&id=III.%20Main%20Reasons%20for%20Performance%20Increase) The primary driver for the anticipated performance increase is the change in accounting treatment following the acquisition of an additional stake in Shanghai Hutchison Pharmaceuticals - The company completed the acquisition of an additional **10% equity stake** in Shanghai Hutchison Pharmaceuticals Co., Ltd. on April 25, 2025, increasing its total holding to **60%** from **50%**[5](index=5&type=chunk)[6](index=6&type=chunk) - Hutchison Pharmaceuticals' accounting method changed from equity method for a joint venture to consolidation as a subsidiary, bringing it into the consolidated financial statements[6](index=6&type=chunk) - According to accounting standards, the re-measurement of previously held equity at fair value upon gaining control due to additional investment, with the difference between fair value and book value recognized as investment income in the current period, is the main reason for the performance increase[6](index=6&type=chunk) [Risk Warning](index=2&type=section&id=IV.%20Risk%20Warning) This section highlights that the performance forecast data is preliminary and unaudited, with no major uncertainties identified as of the disclosure date - The data in this performance forecast is a preliminary estimate by the finance department and has not been audited by an accounting firm[7](index=7&type=chunk) - As of the disclosure date, the company has not identified any significant uncertainties affecting the accuracy of this performance forecast[7](index=7&type=chunk) [Other Explanatory Matters](index=2&type=section&id=V.%20Other%20Explanatory%20Matters) Investors are advised to exercise caution as the forecast data is preliminary, and the final accurate financial figures will be based on the official 2025 semi-annual report - The forecast data is preliminary, and the specific accurate financial data will be subject to the company's officially disclosed 2025 semi-annual report[8](index=8&type=chunk) - Investors are reminded to make prudent decisions and be aware of investment risks[8](index=8&type=chunk)

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) expects a net profit of 4.45 billion yuan for the first half of 2025, representing a year-on-year increase of approximately 52% due to the acquisition of a 10% stake in Yangtze Pharmaceutical [1] Financial Performance - The anticipated net profit for the first half of 2025 is 4.45 billion yuan, an increase of 1.508 billion yuan compared to the same period last year [1] - The growth in profit is primarily attributed to the completion of the acquisition of Yangtze Pharmaceutical in April 2025, which will be included in the consolidated financial statements [1]

Core Points - The announcement details the results of the third exercise period for the stock option incentive plan of Shanghai Pharmaceuticals, indicating that no options were exercised during the second quarter of 2025 [4][11] - The total number of stock options available for the third exercise period is 680,000, with the exercise period running from February 8, 2025, to February 7, 2026 [4][11] - The company has followed all necessary approval procedures for the stock option incentive plan, including independent opinions from directors and the supervisory board [2][3][5] Approval Process - The company’s board approved the stock option incentive plan and its management measures, with independent directors providing their opinions and the supervisory board conducting necessary checks [2][3][5] - The plan was initially approved by the State-owned Assets Supervision and Administration Commission [1][2] Exercise Details - As of the second quarter of 2025, the number of individuals eligible to exercise the options is 20, but none have exercised their options [7][11] - The stock options are to be issued as ordinary shares (A-shares) to the incentive targets [7][9] Impact on Financials - The lack of exercised options during the third exercise period has not had a significant impact on the company's financial status or operating results as of the end of the second quarter of 2025 [11]

Core Viewpoint - Shanghai Pharmaceuticals Holding Co., Ltd. has completed the share buyback plan initiated by its controlling shareholder, Shanghai Industrial (Group) Co., Ltd., reflecting confidence in the company's future development and value recognition [1][2]. Group 1: Buyback Plan Details - The buyback plan was disclosed on September 14, 2024, with a duration from September 13, 2024, to September 12, 2025, allowing for a maximum increase of 2% of the company's total voting rights [2][3]. - As of June 25, 2025, the controlling shareholder has acquired a total of 74,000,000 H shares, representing approximately 8.052% of the total issued H shares and 1.995% of the total issued shares [1][3]. Group 2: Shareholding Structure Post-Buyback - After the completion of the buyback, the controlling shareholder holds a total of 1,426,255,837 shares, accounting for approximately 38.461% of the total issued shares, with 300,438,000 H shares representing about 32.689% of the total issued H shares [1][2]. - The buyback did not involve any reduction in the shares held by the controlling shareholder during the buyback period [1].

上海医药集团股份有限公司（以下简称"上海医药"或"公司"）控股股东 上海实业（集团）有限公司（以下简称"上实集团"）基于对上海医药未来发展 前景的信心及对其价值的认可，计划自 2024 年 9 月 13 日起 12 个月内通过下属 全资子公司上实国际投资有限公司（以下简称"上实国际"）于二级市场增持公 司 H 股股份，增持比例不超过公司投票权的 2%（详见公司公告临 2024-084 号， 以下统称"本次增持计划"）。 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 已披露增持计划情况 证券代码：601607 证券简称：上海医药 公告编号：临 2025-066 上海医药集团股份有限公司 关于控股股东增持计划实施完毕 暨增持股份结果公告 增持计划的实施结果 自本次增持计划披露以来，截至 2025 年 6 月 25 日，上实集团增持本公司 H 股股份计划已经实施完毕。本次增持期间内，上实集团通过上实国际增持了本公 司H股股份共计74,000,000股，约占本公司已发行H股股份总数（即919,072,704 ...

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於控股股東增持計畫實施完畢暨增持股份結果公告》、 《上海市錦天城律師事務所關於上海實業（集團）有限公司及其一致行動人增持上海醫藥 H 股股份免於發出要約事宜的法律意見書》、《上海醫藥集團股份有限公司關於 2019 年 A 股股 票期權激勵計畫預留股票期權第三個行權期 2025 年第二季度自主行權結果公告》、《上海醫 藥集團股份有限公司關於 2019 年 A 股股票期權激勵計畫預留股票期權第三個行權期限制行 權期 ...

证券代码：601607 证券简称：上海医药 公告编号：临2025-066 上海医药集团股份有限公司 关于控股股东增持计划实施完毕 暨增持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 已披露增持计划情况 上海医药集团股份有限公司（以下简称"上海医药"或"公司"）控股股东 上海实业（集团）有限公司（以下简称"上实集团"）基于对上海医药未来发展 前景的信心及对其价值的认可，计划自 2024 年 9 月 13 日起 12 个月内通过下属 全资子公司上实国际投资有限公司（以下简称"上实国际"）于二级市场增持公 司 H 股股份，增持比例不超过公司投票权的 2%（详见公司公告临 2024-084 号， 以下统称"本次增持计划"）。 增持计划的实施结果 自本次增持计划披露以来，截至 2025 年 6 月 25 日，上实集团增持本公司 H 股股份计划已经实施完毕。本次增持期间内，上实集团通过上实国际增持了本公 司H股股份共计74,000,000股，约占本公司已发行H股股份总数（即919,072,704 ...